Literature DB >> 7957535

Characterization of cyclosporine A uptake in human erythrocytes.

C Reichel1, M von Falkenhausen, D Brockmeier, H J Dengler.   

Abstract

More than 70% of cyclosporine A (CsA) is bound to erythrocytes at whole blood concentrations of 50-1000 ng.ml-1. Cytosolic CsA is bound to the erythrocyte peptidyl-prolyl cis-trans isomerase cyclophilin. Measurements of serum CsA levels under clinical conditions are hampered by a temperature-dependent translocation of CsA into erythrocytes during cooling of the probes to room temperature. In order to characterize the kinetics of CsA uptake and to find a specific uptake inhibitor, we developed a method to measure the velocity of uptake based on rapid cooling of the erythrocyte suspension. The total erythrocyte-binding capacity for CsA amounted to 43 x 10(-5) nmol per 10(6) erythrocytes or 2.6 x 10(5) molecules per erythrocyte. Whereas the erythrocyte-binding capacity of CsA was temperature-independent between 10 degrees C and 42 degrees C, uptake kinetics of CsA were temperature-dependent. The Arrhenius plot for CsA uptake in human erythrocytes was linear and no transition temperature between 0 degree C and 42 degrees C could be detected. Therefore the CsA uptake process in human erythrocytes did not fulfil the criteria of carrier-mediated transport. This indicates that CsA diffuses passively into human erythrocytes. Hence, erythrocyte CsA uptake cannot be specifically inhibited.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957535     DOI: 10.1007/BF00191903

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

Review 1.  Cyclosporin A and its metabolites, distribution in blood and tissues.

Authors:  H Akagi; A Reynolds; M Hjelm
Journal:  J Int Med Res       Date:  1991 Jan-Feb       Impact factor: 1.671

2.  Mechanisms of gentamicin transport in kidney epithelial cell line (LLC-PK1).

Authors:  H Saito; K Inui; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

3.  Measurement of cyclosporin A and of four metabolites in whole blood by high-performance liquid chromatography.

Authors:  U Christians; K O Zimmer; K Wonigeit; K F Sewing
Journal:  J Chromatogr       Date:  1987-01-23

4.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

5.  Identification of cyclophilin as the erythrocyte ciclosporin-binding protein.

Authors:  B M Foxwell; G Frazer; M Winters; P Hiestand; R Wenger; B Ryffel
Journal:  Biochim Biophys Acta       Date:  1988-03-03

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Transport of cyclosporin A in kidney epithelial cell line (LLC-PK1).

Authors:  A Takayama; Y Okazaki; K Fukuda; M Takano; K Inui; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1991-04       Impact factor: 4.030

8.  Cyclosporin receptors on human lymphocytes.

Authors:  B Ryffel; U Götz; B Heuberger
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

9.  Uptake and nature of the intracellular binding of cyclosporin A in a murine thymoma cell line, BW5147.

Authors:  M P Merker; M M Merker; R E Handschumacher
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

10.  Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat.

Authors:  S Urien; R Zini; M Lemaire; J P Tillement
Journal:  J Pharmacol Exp Ther       Date:  1990-04       Impact factor: 4.030

View more
  3 in total

Review 1.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.

Authors:  Sam Hopkins; Bernard Scorneaux; Zhuhui Huang; Michael G Murray; Stephen Wring; Craig Smitley; Richard Harris; Frank Erdmann; Gunter Fischer; Yves Ribeill
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

3.  Pharmacokinetic profile and partitioning in red blood cells of romifidine after single intravenous administration in the horse.

Authors:  Noemi Romagnoli; Khaled M Al-Qudah; Sara Armorini; Carlotta Lambertini; Anna Zaghini; Alessandro Spadari; Paola Roncada
Journal:  Vet Med Sci       Date:  2017-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.